Home » COREVALVE TO COMMENCE REVALVING SYSTEM CLINICAL TRIAL
COREVALVE TO COMMENCE REVALVING SYSTEM CLINICAL TRIAL
CoreValve has received approval from the German government - Bezirksregierung Koln, state of Nordrhein-Westfalen, Cologne -- to immediately commence a clinical trial of its proprietary ReValving System to nonsurgically replace diseased aortic heart valves in 10 patients who are contraindicated for open-heart surgery. Previously, CoreValve received "local" IRB approval from The Heart Center, Seigburg, Germany, where the clinical trial will take place.
Business Wire
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
18Jul
-
21Oct